NRC and KalGene Develop New Alzheimer's Treatment

This is part of NRC's new role as contract help for industry. Take it as you will.

To assist with the evaluation of the therapy, the Montreal Neurological Institute is providing best-in-class human imaging, while the Centre for Imaging Technology Commercialization (CIMTEC) is developing an algorithm to automatically quantify amyloid-beta, the suspected cause of Alzheimer’s disease.